Literature DB >> 16777967

Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas.

Kevin G Chen1, Julio C Valencia, Barry Lai, Guofeng Zhang, Jill K Paterson, François Rouzaud, Werner Berens, Stephen M Wincovitch, Susan H Garfield, Richard D Leapman, Vincent J Hearing, Michael M Gottesman.   

Abstract

Multidrug resistance mechanisms underlying the intractability of malignant melanomas remain largely unknown. In this study, we demonstrate that the development of multidrug resistance in melanomas involves subcellular sequestration of intracellular cytotoxic drugs such as cis-diaminedichloroplatinum II (cisplatin; CDDP). CDDP is initially sequestered in subcellular organelles such as melanosomes, which significantly reduces its nuclear localization when compared with nonmelanoma/KB-3-1 epidermoid carcinoma cells. The melanosomal accumulation of CDDP remarkably modulates melanogenesis through a pronounced increase in tyrosinase activity. The altered melanogenesis manifested an approximately 8-fold increase in both intracellular pigmentation and extracellular transport of melanosomes containing CDDP. Thus, our experiments provide evidence that melanosomes contribute to the refractory properties of melanoma cells by sequestering cytotoxic drugs and increasing melanosome-mediated drug export. Preventing melanosomal sequestration of cytotoxic drugs by inhibiting the functions of melanosomes may have great potential as an approach to improving the chemosensitivity of melanoma cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16777967      PMCID: PMC1502551          DOI: 10.1073/pnas.0600213103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  TYRP2-mediated resistance to cis-diamminedichloroplatinum (II) in human melanoma cells is independent of tyrosinase and TYRP1 expression and melanin content.

Authors:  B J Pak; Q Li; R S Kerbel; Y Ben-David
Journal:  Melanoma Res       Date:  2000-10       Impact factor: 3.599

2.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

3.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Richard M Sherry; Suzanne L Topalian; Nicholas P Restifo; Richard E Royal; Udai Kammula; Don E White; Sharon A Mavroukakis; Linda J Rogers; Gerald J Gracia; Stephanie A Jones; David P Mangiameli; Michelle M Pelletier; Juan Gea-Banacloche; Michael R Robinson; David M Berman; Armando C Filie; Andrea Abati; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

4.  Distribution and mRNA expression of insulin-like growth factor system in pulmonary lymphangioleiomyomatosis.

Authors:  J C Valencia; K Matsui; C Bondy; J Zhou; A Rasmussen; K Cullen; Z X Yu; J Moss; V J Ferrans
Journal:  J Investig Med       Date:  2001-09       Impact factor: 2.895

5.  A model for melanosome biogenesis based on the purification and analysis of early melanosomes.

Authors:  T Kushimoto; V Basrur; J Valencia; J Matsunaga; W D Vieira; V J Ferrans; J Muller; E Appella; V J Hearing
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

6.  The direct mapping of the uptake of platinum anticancer agents in individual human ovarian adenocarcinoma cells using a hard X-ray microprobe.

Authors:  Petr Ilinski; Barry Lai; Zhonghou Cai; Wenbing Yun; Daniel Legnini; Teresa Talarico; Marian Cholewa; Lorraine K Webster; Glen B Deacon; Silvina Rainone; Don R Phillips; Anton P J Stampfl
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

7.  Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake.

Authors:  D W Shen; S Goldenberg; I Pastan; M M Gottesman
Journal:  J Cell Physiol       Date:  2000-04       Impact factor: 6.384

Review 8.  Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets.

Authors:  D Grossman; D C Altieri
Journal:  Cancer Metastasis Rev       Date:  2001       Impact factor: 9.264

9.  Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines.

Authors:  S S Chauhan; X J Liang; A W Su; A Pai-Panandiker; D W Shen; J A Hanover; M M Gottesman
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

Review 10.  Human melanoma: drug resistance.

Authors:  Heike Helmbach; Pranav Sinha; Dirk Schadendorf
Journal:  Recent Results Cancer Res       Date:  2003
View more
  56 in total

1.  Evaluation of new iodinated acridine derivatives for targeted radionuclide therapy of melanoma using 125I, an Auger electron emitter.

Authors:  Maryline Gardette; Janine Papon; Mathilde Bonnet; Nicolas Desbois; Pierre Labarre; Ting-Dee Wu; Elisabeth Miot-Noirault; Jean-Claude Madelmont; Jean-Luc Guerquin-Kern; Jean-Michel Chezal; Nicole Moins
Journal:  Invest New Drugs       Date:  2010-06-22       Impact factor: 3.850

2.  A somatic mutation of the KEAP1 gene in malignant melanoma is involved in aberrant NRF2 activation and an increase in intrinsic drug resistance.

Authors:  Shinpei Miura; Masahiko Shibazaki; Shuya Kasai; Shinji Yasuhira; Ayano Watanabe; Tsuyoshi Inoue; Yuich Kageshita; Kanako Tsunoda; Kazuhiro Takahashi; Toshihide Akasaka; Tomoyuki Masuda; Chihaya Maesawa
Journal:  J Invest Dermatol       Date:  2013-08-12       Impact factor: 8.551

Review 3.  In situ imaging of metals in cells and tissues.

Authors:  Reagan McRae; Pritha Bagchi; S Sumalekshmy; Christoph J Fahrni
Journal:  Chem Rev       Date:  2009-10       Impact factor: 60.622

4.  Melanin transfer: the keratinocytes are more than gluttons.

Authors:  Cédric Delevoye
Journal:  J Invest Dermatol       Date:  2014-04       Impact factor: 8.551

5.  Melatonin exerts oncostatic capacity and decreases melanogenesis in human MNT-1 melanoma cells.

Authors:  Konrad Kleszczyński; Tae-Kang Kim; Bernadetta Bilska; Michal Sarna; Krystian Mokrzynski; Agatha Stegemann; Elżbieta Pyza; Russel J Reiter; Kerstin Steinbrink; Markus Böhm; Andrzej T Slominski
Journal:  J Pineal Res       Date:  2019-10-07       Impact factor: 13.007

6.  Stable synthetic bacteriochlorins overcome the resistance of melanoma to photodynamic therapy.

Authors:  Pawel Mroz; Ying-Ying Huang; Angelika Szokalska; Timur Zhiyentayev; Sahar Janjua; Artemissia-Phoebe Nifli; Margaret E Sherwood; Christian Ruzié; K Eszter Borbas; Dazhong Fan; Michael Krayer; Thiagarajan Balasubramanian; Eunkyung Yang; Hooi Ling Kee; Christine Kirmaier; James R Diers; David F Bocian; Dewey Holten; Jonathan S Lindsey; Michael R Hamblin
Journal:  FASEB J       Date:  2010-04-12       Impact factor: 5.191

Review 7.  Opportunities in multidimensional trace metal imaging: taking copper-associated disease research to the next level.

Authors:  Stefan Vogt; Martina Ralle
Journal:  Anal Bioanal Chem       Date:  2012-10-19       Impact factor: 4.142

8.  Influence of melanosome dynamics on melanoma drug sensitivity.

Authors:  Kevin G Chen; Richard D Leapman; Guofeng Zhang; Barry Lai; Julio C Valencia; Carol O Cardarelli; Wilfred D Vieira; Vincent J Hearing; Michael M Gottesman
Journal:  J Natl Cancer Inst       Date:  2009-08-24       Impact factor: 13.506

9.  Molecular markers of tumor progression in melanoma.

Authors:  Joshua Rother; Dan Jones
Journal:  Curr Genomics       Date:  2009-06       Impact factor: 2.236

10.  Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma.

Authors:  B Keenen; H Qi; S V Saladi; M Yeung; I L de la Serna
Journal:  Oncogene       Date:  2009-09-28       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.